Reuters logo
BRIEF-Bellus Health's BLU-5937 reduces cough without taste disturbance in two preclinical models
September 18, 2017 / 11:18 AM / in a month

BRIEF-Bellus Health's BLU-5937 reduces cough without taste disturbance in two preclinical models

Sept 18 (Reuters) - Bellus Health Inc

* Bellus Health’s BLU-5937 significantly reduces cough without taste disturbance in two preclinical models

* Bellus Health Inc - BLU-5937’s reduction in cough frequency comparable to leading P2X3 antagonist, Gefapixant

* Bellus - in rat taste model, BLU-5937 didnt inhibit taste; but consistent with trial data presented by Merck, Gefapixant did significantly impact taste Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below